The Division of Hematology and Oncology at the Medical College of Wisconsin has a talented team of physicians, advanced practice providers, nurses, research and administrative staff that are all focused on patient centered clinical care and research in the pursuit of better therapies for cancer. The Division is part of the Department of Medicine and functions within the framework of Medical College of Wisconsin Cancer Center. Our expertise extends to all aspects of medical oncology including treatment of solid tumors, hematologic (blood) cancers, bone marrow transplantation and cellular therapies. Our Palliative Care section provides expert consultation in quality of life issues across the continuum of care for patients facing serious illnesses.

We provide state-of-the-art care in oncology. This means that our faculty are sub-specialists who are well-known experts in their field with a focus on just one or two cancer types. This disease focus also allows our cancer specialists to bring the most advanced clinical trials in their disciplines to their patients. Multidisciplinary care involves close collaboration with our colleagues in Radiation Oncology, Surgical Oncology, Urologic Oncology and Gynecological Oncology as well as other specialists at Froedtert & The Medical College of Wisconsin. Our internationally renowned Bone Marrow Transplant Program has survival outcomes at the very top of the national rankings and is involved in innovative cell therapy research. Similar programs for blood cancers (leukemia, lymphoma and myeloma) and common solid tumors (breast, colon, pancreas, head and neck, lung, genitourinary cancers) ensure that patients in southeastern Wisconsin have access to the best in cancer care. Research done in the Division spans all aspects of cancer care including cancer prevention, epidemiology, immunology, drug development and pharmacotherapy as well as all phases of clinical trials. As a Division, we are engaged in a variety of efforts to improve the awareness and knowledge about these illnesses and cancer survivorship in our region among the public, fellow physicians and other providers.

Our faculty and staff have grown more than threefold in the past seven years and we have significantly expanded both our ambulatory and in-patient facilities. More importantly, growth in the programs and services for our patients, access to cutting edge research, and clinical trials for difficult diseases has been equally impressive. We can offer our patients unique therapies not found elsewhere in this region.